Prostate:前列腺癌男性患者需求的定量分析

2020-02-14 AlexYang MedSci原创

恶性前列腺癌(PCa)男性患者的指南最近有所变化,包括了遗传咨询(GC)和/或遗传测试(GT)。最近,有研究人员鉴定了PCa男性患者在GC之前和从GC中想获得的信息情况。研究的小组中包括了PCa男性患者,研究人员对交流进行了录音,并对与GT相关的主题、他们期望从健康护理者中想获得的信息以及与家庭成员有关的一些信息进行了分析。研究中共有37名PCa男性患者,共有7个焦点小组。研究发现,几乎所有的男性

恶性前列腺癌(PCa)男性患者的指南最近有所变化,包括了遗传咨询(GC)和/或遗传测试(GT)。最近,有研究人员鉴定了PCa男性患者在GC之前和从GC中想获得的信息情况。

研究的小组中包括了PCa男性患者,研究人员对交流进行了录音,并对与GT相关的主题、他们期望从健康护理者中想获得的信息以及与家庭成员有关的一些信息进行了分析。研究中共有37名PCa男性患者,共有7个焦点小组。研究发现,几乎所有的男性均认为GT是有益的且对家庭和自身具有影响。大多数男性并不清楚他们的女性亲属患有遗传性癌症的风险。参与者认为遗传情况应该包含在诊断过程的合适时间。

最后,研究人员指出,他们的研究表明了PCa男性看重GC和GT对个人和家庭的影响,但是通常不会联系女性亲属发展为癌症与PCa遗传的相关性。因此,在他们治疗的过程中应该考虑GC。另外,医护人员可以利用患者的动机和使用与患者的关系来确定合适的时机,并且与患者个性化讨论GC和GT。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1933374, encodeId=87d519333e491, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sun Jul 26 16:09:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054107, encodeId=d052205410e1a, content=<a href='/topic/show?id=c699e024409' target=_blank style='color:#2F92EE;'>#男性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70244, encryptionId=c699e024409, topicName=男性患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Feb 23 02:09:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364563, encodeId=9fa813645633d, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602234, encodeId=a76b1602234c9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040662, encodeId=69d11040662b7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 14 17:09:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1933374, encodeId=87d519333e491, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sun Jul 26 16:09:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054107, encodeId=d052205410e1a, content=<a href='/topic/show?id=c699e024409' target=_blank style='color:#2F92EE;'>#男性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70244, encryptionId=c699e024409, topicName=男性患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Feb 23 02:09:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364563, encodeId=9fa813645633d, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602234, encodeId=a76b1602234c9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040662, encodeId=69d11040662b7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 14 17:09:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1933374, encodeId=87d519333e491, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sun Jul 26 16:09:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054107, encodeId=d052205410e1a, content=<a href='/topic/show?id=c699e024409' target=_blank style='color:#2F92EE;'>#男性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70244, encryptionId=c699e024409, topicName=男性患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Feb 23 02:09:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364563, encodeId=9fa813645633d, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602234, encodeId=a76b1602234c9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040662, encodeId=69d11040662b7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 14 17:09:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2020-02-16 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1933374, encodeId=87d519333e491, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sun Jul 26 16:09:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054107, encodeId=d052205410e1a, content=<a href='/topic/show?id=c699e024409' target=_blank style='color:#2F92EE;'>#男性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70244, encryptionId=c699e024409, topicName=男性患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Feb 23 02:09:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364563, encodeId=9fa813645633d, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602234, encodeId=a76b1602234c9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040662, encodeId=69d11040662b7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 14 17:09:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2020-02-16 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1933374, encodeId=87d519333e491, content=<a href='/topic/show?id=eaf54598041' target=_blank style='color:#2F92EE;'>#定量分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45980, encryptionId=eaf54598041, topicName=定量分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Sun Jul 26 16:09:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054107, encodeId=d052205410e1a, content=<a href='/topic/show?id=c699e024409' target=_blank style='color:#2F92EE;'>#男性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70244, encryptionId=c699e024409, topicName=男性患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Sun Feb 23 02:09:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364563, encodeId=9fa813645633d, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602234, encodeId=a76b1602234c9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Feb 16 05:09:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040662, encodeId=69d11040662b7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Feb 14 17:09:00 CST 2020, time=2020-02-14, status=1, ipAttribution=)]
    2020-02-14 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

口服雄激素受体抑制剂Nubeqa在III期前列腺癌研究中取得成功

拜耳和Orion的联合开发药物口服雄激素受体抑制剂Nubeqa(darolutamide)可显着提高非转移性去势抵抗性前列腺癌男性患者的整体生存率。

Oncogene:GRK2能够增强前列腺和前列腺肿瘤的雄激素受体依赖性

发展成为雄激素阻断治疗抗性的转移性肿瘤是前列腺癌治疗的主要挑战。尽管这些复发性肿瘤依赖于雄激素受体(AR),非AR驱使的肿瘤也越来越流行且致死。最近,有研究人员呈现了一个新的遗传工程建立的非AR驱使的前列腺癌小鼠模型,并聚焦一个与G蛋白耦合的受体负调控因子,该因子在恶性人类前列腺肿瘤中下调。因此,转基因小鼠模型中,前列腺特异性表达显性-负G蛋白偶联受体激酶2 (GRK2-DN)能够减少AR和AR靶

2019 CUA/CUOG指南:转移性单纯去势和去势敏感型前列腺癌

2019年12月,加拿大泌尿外科协会(CUA)联合加拿大泌尿肿瘤组(CUOG)共同发布了转移性单纯去势和去势敏感型前列腺癌的管理指南,转移性前列腺癌仍是一种无法治愈的疾病,本文主要针对转移性单纯去势和去势敏感型前列腺癌的管理提出指导见。

Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处

Trovagene是一家临床阶段的肿瘤治疗公司,其研究性新药Onvansertib预期用于治疗包括前列腺癌、结肠直肠癌和白血病在内的多种癌症,该公司近日宣布,正在进行的Onvansertib与Zytiga联合治疗转移性去势抵抗性前列腺癌(mCRPC)的II期试验取得了积极结果。

Sci Rep:牛蒡甙元能够通过对脂肪组织和肿瘤的双重作用来抑制前列腺肿瘤的生长

最近,有研究人员调查了牛蒡甙元-一种新的抗炎症木酚素,在肥胖条件下,体内和体外试验中对前列腺癌的抑制作用情况。研究中,体外肥胖模型通过共培养脂肪细胞3T3-L1与雄激素敏感性LNCaP人类前列腺癌细胞,或者在脂肪细胞条件培养基中培养LNCaP细胞来建立。研究发现,牛蒡甙元能够显著的抑制LNCaP增殖,并减少雄激素受体(AR)和增加Nkx3.1细胞表达。研究人员将人类前列腺癌LAPC-4异种种植肿瘤

Sci Rep:术前%p2PSA和前列腺健康指数能够预测根治性前列腺切除前列腺癌患者的病理结果

最近,有研究人员评估了%p2PSA和前列腺健康指数(PHI)在预测经历根治性前列腺切除术(RP)前列腺癌(PCa)患者的侵袭性病理结果的预测准确性情况。研究人员招募了91名器官受限的PCa患者,他们均经历了机器人辅助的RP治疗。之后,研究人员调查了p2PSA水平和PHI在预测病理性结果方面的能力。研究发现,%p2PSA和PHI在≥pT3疾病、高风险疾病和阳性手术切缘以及精囊浸润(SVI)的患者中显